|1.||Liu, Xinmin: 1 article (01/2014)|
|2.||Li, Datong: 1 article (01/2014)|
|3.||Xi, Yuling: 1 article (01/2014)|
|4.||Ding, Yi: 1 article (01/2014)|
|5.||Lu, Zhongmin: 1 article (01/2014)|
|6.||Chen, Ming: 1 article (01/2014)|
|7.||Soderstrom, Cathy: 1 article (02/2005)|
|8.||Ralston, Sherry: 1 article (02/2005)|
|9.||Kath, John C: 1 article (02/2005)|
|10.||Tkalcevic, George: 1 article (02/2005)|
01/01/2014 - "Furthermore, CP-673451 is effective at suppressing NSCLC tumor growth in vivo. "
02/01/2005 - "The antitumor efficacy of CP-673,451 was evaluated in a number of human tumor xenografts grown s.c. "
02/01/2005 - "Inhibition of PDGFR-beta phosphorylation in tumors correlates with plasma and tumor levels of CP-673,451. "
02/01/2005 - "Multiple models have been used to evaluate in vivo activity of CP-673,451 and to understand the pharmacology of PDGFR-beta inhibition and the effect on tumor growth. "
02/01/2005 - "These data show that CP-673,451 is a pharmacologically selective PDGFR inhibitor, inhibits tumor PDGFR-beta phosphorylation, selectively inhibits PDGF-BB-stimulated angiogenesis in vivo, and causes significant tumor growth inhibition in multiple human xenograft models."
|2.||Lung Neoplasms (Lung Cancer)
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)
|2.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|4.||platelet-derived growth factor BB (becaplermin)
|1.||Heterologous Transplantation (Xenotransplantation)